Literature DB >> 3018092

Association of HTLV-III with Epstein-Barr virus infection and abnormalities of T lymphocytes in homosexual men.

C R Rinaldo, L A Kingsley, D W Lyter, B S Rabin, R W Atchison, A J Bodner, S H Weiss, W C Saxinger.   

Abstract

Homosexual men were studied for associations among human T-lymphotropic virus type III (HTLV-III) infection, Epstein-Barr virus (EBV) infection, and T cell abnormalities. The presence of IgG antibody to EBV capsid antigen and antibody to EBV early antigen was significantly associated with augmented counts of suppressor T cells in healthy HTLV-III-seronegative men. HTLV-III-seropositive asymptomatic subjects had significantly enhanced titers of antibody to EBV and lower ratios of helper to suppressor T cells compared with HTLV-III-seronegative homosexual men. Of three men who seroconverted to HTLV-III, two had a greater than fourfold increase in titer of IgG antibody to EBV capsid antigen after seroconversion. These results suggest that the interaction of HTLV-III and EBV and their immunologic perturbations are significant in the natural history of this retrovirus infection in homosexual men.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018092     DOI: 10.1093/infdis/154.4.556

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 2.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.

Authors:  T Ooka; M de Turenne-Tessier; M C Stolzenberg
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Seroepidemiological correlations of antibodies to human herpesviruses and human immunodeficiency virus type 1 in African patients.

Authors:  S Essers; A Schwinn; J ter Meulen; H von Lips; K Dietz; F S Mhalu; J Shao; V ter Meulen
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

4.  Immunological study of the rectal mucosa of men with and without human immunodeficiency virus infection.

Authors:  P E Bishop; A McMillan; H M Gilmour
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

5.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.

Authors:  S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

6.  Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus.

Authors:  M A Rahman; L A Kingsley; R W Atchison; S Belle; M C Breinig; M Ho; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

7.  Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion.

Authors:  A Schattner; N Hanuka; B Sarov; I Sarov; Z Handzel; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

8.  Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection.

Authors:  R Enzensberger; W Braun; C July; E B Helm; H W Doerr
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

9.  Association between HIV and other DNA viruses in vitro.

Authors:  R Cisterna; C Campelo; T Gorriño; C Malavé; L Sarría; P Lardelli; A Fernandez de Aranguiz; L Madariaga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

10.  An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.

Authors:  S Kenney; J Kamine; D Markovitz; R Fenrick; J Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.